Cochrane, the global organization that systematically reviews medical evidence, has conducted the most comprehensive examination of acne treatments available—and the findings may surprise you. A 2024 Cochrane overview that pooled data from 6 systematic reviews covering 40,910 people with acne across 275 studies found that no acne therapy currently has high-certainty evidence supporting its use. This doesn’t mean nothing works; it means the research quality behind most treatments falls short of the rigorous standards Cochrane uses to declare something truly effective.
If you’ve been prescribed benzoyl peroxide, tried light therapy, or considered other topical treatments, understanding what Cochrane actually found will help you make more informed decisions about which approaches have real backing and which are being used more out of convention than proof. This article examines the Cochrane evidence for the most common acne treatments, what their reviews reveal about effectiveness and side effects, why so many studies fail to meet higher evidence standards, and how to interpret these findings when choosing your own treatment path. The gap between “commonly prescribed” and “well-researched” is wider in dermatology than many people realize, and Cochrane’s work shines a light on exactly where that gap exists.
Table of Contents
- What Does Cochrane Say About Current Acne Treatment Evidence?
- The Challenge of Limited Evidence Quality in Acne Research
- Benzoyl Peroxide: What the Data Really Shows
- Light Therapies and Other Topical Treatments: Inconclusive Evidence
- Treating Acne Scars: Where the Evidence Falls Short
- Why This Evidence Gap Matters for Your Treatment Choices
- Moving Forward: What High-Certainty Evidence Looks Like in Dermatology
- Conclusion
What Does Cochrane Say About Current Acne Treatment Evidence?
Cochrane’s systematic approach starts with a simple question: what does the best available research actually show about acne treatments? To answer this, they don’t just look at individual studies—they examine multiple systematic reviews to get the broadest possible view. Their 2024 overview looked at 6 major systematic reviews involving hundreds of individual randomized controlled trials. The scope was substantial: 40,910 people with active acne, 1,316 people with acne scars, and nearly 1,400 studies total feeding into the analysis. The headline finding is stark: Cochrane found zero high-certainty evidence for any acne therapy they assessed.
Let that sink in. This doesn’t mean all treatments are equally useless, but it means even the most commonly prescribed interventions—the ones dermatologists reach for regularly—lack the gold-standard evidence that Cochrane requires to claim something is definitively effective. Instead, most treatments were rated as having “very low” to “moderate” certainty evidence. For comparison, if you were diagnosed with a bacterial infection, antibiotics would have high-certainty evidence. Acne treatments are nowhere near that level of proof.
The Challenge of Limited Evidence Quality in Acne Research
Why does acne treatment evidence lag so far behind other medical fields? Part of the answer lies in how acne trials are designed and conducted. Cochrane noted that randomized controlled trials related to acne often have low methodological quality—meaning they’re poorly designed, have small sample sizes, or lack proper blinding and control groups. These weaknesses compound when trying to draw firm conclusions. A trial with 50 participants is valuable, but it’s not the same as a trial with 1,000 participants. A study where patients know whether they’re using the active treatment or placebo produces less reliable results than one where neither the patient nor the researcher knows (double-blinding). However, if your dermatologist has prescribed something that Cochrane rates as “low certainty” or “moderate certainty,” that’s not automatically a red flag.
It means the evidence isn’t perfect, not that the treatment doesn’t work. dermatologists often make treatment decisions based on the best available evidence, even when that evidence is imperfect. The gap between “not high-certainty” and “ineffective” is crucial. Think of it this way: the evidence might show a treatment helps 60% of people in trials, but we’re not 100% certain that percentage applies to everyone. That’s a “moderate certainty” conclusion. It’s still useful information for treatment decisions, but it’s not the level of proof we’d have if hundreds of thousands of people had been studied over decades.
Benzoyl Peroxide: What the Data Really Shows
Benzoyl peroxide is perhaps the most studied topical acne treatment—it’s been around for decades and is available over the counter. Cochrane’s review of benzoyl peroxide found that across 2 trials involving 1,012 participants, benzoyl peroxide may reduce total and inflammatory lesion counts compared to placebo. The word “may” is important: the evidence is described as “very uncertain,” meaning the true effect might be larger, smaller, or even absent. In practical terms, if you’re considering benzoyl peroxide based on this evidence alone, you’re betting on a treatment that might help reduce acne lesions but with significant uncertainty about how much it will actually help you specifically. When it comes to how people feel about their acne overall, the picture becomes murkier.
In 2 separate trials with 1,073 participants, benzoyl peroxide showed little to no effect on global self-assessment—meaning participants didn’t rate their acne as noticeably better even if lesion counts technically decreased. This is an important distinction. A treatment might reduce the number of lesions but not actually improve how clear your skin looks or feels to you. Additionally, benzoyl peroxide carries a side effect burden. Across 13 trials involving 4,287 participants over 10-12 weeks, benzoyl peroxide may increase the risk of mild-to-moderate adverse events like dryness, irritation, redness, and rash compared to placebo. For someone with already sensitive skin, this tradeoff might not be worth the modest benefit.
Light Therapies and Other Topical Treatments: Inconclusive Evidence
Light-based therapies—including blue light, red light, and combined wavelength treatments—have gained popularity in acne clinics and at-home devices. The appeal is obvious: a non-chemical, potentially less irritating approach to clearing skin. However, Cochrane’s review of light therapies for acne found that evidence is insufficient to draw firm conclusions about their effectiveness versus placebo, no treatment, or topical treatments. Even more concerning, the duration of any potential benefits remains unclear.
A treatment that improves acne for two weeks but then loses effectiveness is different from one that provides lasting benefit, but many light therapy trials don’t follow patients long enough to answer this question. This uncertainty doesn’t mean light therapies don’t work for anyone—it means the research hasn’t robustly proven they work for most people. When comparing acne treatments, remember this principle: treatments that seem cutting-edge or expensive aren’t automatically better-researched than older, cheaper alternatives. In fact, newer light therapy devices often have less evidence behind them than benzoyl peroxide simply because fewer studies have been conducted. If you’re considering investing in a light therapy device or clinic treatments, ask your dermatologist for the specific trial data supporting its use, and expect an honest answer about uncertainty.
Treating Acne Scars: Where the Evidence Falls Short
Acne scars represent a different problem than active acne, and the research situation is similarly constrained. Cochrane reviewed 37 studies involving 1,316 people with acne scars and found moderate-quality evidence that injectable fillers may be effective for atrophic (depressed) acne scars. That’s the most encouraging finding in the acne scar literature—”may be effective” based on moderate evidence. However, there’s a critical limitation: no long-term follow-up studies exist. Injectable fillers require repeated treatments as the body breaks down the material, but Cochrane found no evidence showing whether the long-term effects are sustainable or how frequently treatments are truly needed.
Beyond injectable fillers, Cochrane found no evidence supporting first-line use of any other intervention for acne scars. Laser treatments, microneedling, chemical peels, and subcision may all be offered by dermatologists, but the research foundation is thin or non-existent. This is particularly important because acne scar treatments are expensive and often elective. If you’re considering scar treatment, the choice becomes somewhat personal: moderate evidence for fillers versus essentially anecdotal support for other approaches. Cochrane’s clear conclusion is that short-term improvements in scar appearance may not translate to the long-term, meaningful outcomes patients hope for.
Why This Evidence Gap Matters for Your Treatment Choices
Understanding Cochrane’s findings requires recognizing why evidence gaps exist. Acne trials are expensive to fund, and unlike pharmaceutical treatments, topical creams and light devices generate interest from multiple companies with competing products. This creates fragmented research. A benzoyl peroxide company funds studies on benzoyl peroxide; a light therapy company funds studies on light therapy. Nobody funds large comparative trials asking “is treatment A actually better than treatment B?” Additionally, acne is chronic and highly individual—what clears one person’s skin may do nothing for another.
This variability makes large-scale evidence harder to generate and interpret. The Cochrane researchers explicitly identified gaps in current research. They noted that future research is needed on topical retinoids (a class of vitamin A derivatives often used in acne treatment), topical antibiotics, and the psychological impacts of acne on quality of life. These are recognized as important but understudied areas. For you as a patient, this means treatments your dermatologist prescribes might fall into these understudy categories—like tretinoin (a retinoid) or doxycycline (an oral antibiotic). The treatments may still be your best option, but understand they’re being used somewhat on clinical experience rather than definitive trial evidence.
Moving Forward: What High-Certainty Evidence Looks Like in Dermatology
To understand what Cochrane considers high-certainty evidence, consider this: they require large sample sizes (ideally over 1,000 participants), long follow-up periods, proper study design, and consistent results across multiple independent trials. In acne research, these conditions are rare. Some other dermatological conditions have better evidence bases—for instance, treatments for fungal infections have higher-certainty evidence than acne treatments.
This disparity reflects funding priorities and research feasibility, not that acne treatments don’t work at all. Looking forward, Cochrane’s work points toward the research agenda dermatologists and patients should advocate for: larger trials with better design, longer follow-up periods, and comparison studies between treatments. Until then, you’re making acne treatment choices based on imperfect evidence. The key is understanding that “imperfect evidence” doesn’t mean “no evidence”—it means approaching treatment with realistic expectations and willingness to adjust if something isn’t working for you personally.
Conclusion
Cochrane’s comprehensive review reveals that acne treatment evidence is far weaker than many patients and providers assume. With no high-certainty evidence for any treatment and most falling into “very low” or “moderate” certainty categories, you’re navigating treatment choices in an evidence desert, not a well-mapped territory. Benzoyl peroxide may help some people but carries side effects and doesn’t reliably improve how skin actually looks. Light therapies remain inconclusive. Even acne scar treatments, where moderate evidence exists for fillers, lack long-term data.
The takeaway isn’t to abandon treatment—it’s to approach acne management with clear-eyed expectations. Work with your dermatologist, but ask directly about evidence levels and be willing to advocate for your own experience. If a treatment isn’t working after a reasonable trial period, that’s important feedback that shouldn’t be ignored. And if you’re considering expensive options like light therapy devices or scar treatments, understanding the evidence limitations helps you make decisions that align with your priorities, whether that’s cost, side effects, or likelihood of effectiveness. Acne is treatable, but the path to clear skin is more individual and less scientifically certain than the acne industry often suggests.
